Bibliography
- Kumari R, Nguyen MH. Fixed-dose combination of sofosbuvir and ledispavir for the treatment of chronic hepatitis C genotype 1. Expert Opin Pharmacother 2015. [Epub ahead of print]
- Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-98
- Afdhal N, Reddy KR, Nelson DR, et al. Ledispavir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-93
- Kowdley KV, Gordon SC, Reddy KR, et al. Ledispavir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879-88
- Reddy KR, Everson GT, Flamm SL, et al. Ledipasvir/Sofosbuvir with ribavirin for the treatment of HCV in patients with post-transplant recurrence: preliminary results of a prospective multicenter study. Hepatology 2014;60(Suppl):200A
- Wyles DL, Pockros PJ, Yang JC, et al. Retreatment of patients who failed prior sofosbuvir-based regimens with all oral fixed-dose combination ledipasvir/sofosbuvir plus ribavirin for 12 weeks. Hepatology 2014;60(Suppl):317A
- Townsend KS, Osinusi A, Nelson AK, et al. High efficacy of sofosbuvir/ledipasvir for the treatment of HCV genotype 1 in patients coinfected with HIV on or off antiretroviral therapy: results from the NIAID ERADICATE trial. Hepatology 2014;60:2040A
- Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C versus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naïve patients in the COSMOS randomized study. Lancet 2014;384:1756-65
- Jensen DM, O’Leary JG, Pockros PJ, et al. Safety and efficacy of sofosbuvir containing regimens for hepatitis C: a real world experience in a diverse longitudinal observational cohort. Hepatology 2014;60(Suppl 1):219A-20A
- Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1594-603
- Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014;370:19831992
- Kohler JJ, Nettles JH, Amblard F, et al. Approaches to hepatitis C treatment and cure using NS5A inhibitors. Infect Drug Resist 2014;7:41-56
- Gane EJ, Hyland RH, An D, et al. Once daily sofosbuvir with GS-5816 for 8 weeks with or without ribavirin in patients with genotype 3 without cirrhosis result inhigh rates of SVR12: the ELECTRON2 study. Hepatology 2014;60(Suppl):236A-7A